Presented by
Falconbury

Drafting Commercial Contracts for the Pharmaceutical Industry

A three-day practical and interactive seminar focusing on current contract drafting, negotiating, best practice and related issues within the pharmaceutical, biotech and life sciences sectors.

24-26 Nov 2021 + 4 more dates

Enrol now

  • Format: Live online, Classroom
  • CPD: 18 hours for your records
  • Certificate of completion

Course overview

In such a highly regulated industry and in these turbulent and uncertain times, understanding the key challenges of negotiation and drafting an effective and watertight contract on an international level are complex topics. They can be difficult for even the most well-equipped in-house lawyer and most often it is not the lawyer in the driving seat. Commercial managers from all areas of the pharmaceutical industry are leading negotiations and drafting and managing key contracts on a daily basis. It is vital that both legal counsel and commercial executives not only have the key skills and tactics to create a win:win scenario but also the knowledge to ensure any agreement is within the laws and regulations. The alternative is the exposure of the organisation to unnecessary risk and costly disputes, especially with the complication of Brexit.

The programme consists of five modules which will:
  • Deliver an in-depth examination of intellectual property issues that affect pharmaceutical industry agreements
  • Focus on competition regulations pertinent to pharmaceutical industry agreements
  • Analyse the commercial and legal issues affecting pharmaceutical industry agreements
  • Examine collaboration and licensing agreements
  • Feature an in-depth workshop on effective negotiation skills

The delivery style
This unique and highly interactive three-day programme looks at all stages of the contracting process and aims to deliver applied training through a balanced blend of practical learning. The presenters will use a mixture of practical exercises and cases from the pharmaceutical industry to ensure you leave the seminar with the knowledge and skills to perfect all stages of the process.

Who should attend?

Personnel from R&D, clinical, regulatory, commercial, sales and marketing, manufacturing, distribution and purchasing functions, including:
  • In-house counsel
  • Commercial and contract managers
  • Business development managers
  • Purchasing and procurement
  • Heads of legal departments
  • Legal advisers
  • Patent, IP, trade marks or licensing counsel

The key objectives

By attending this seminar, you will:
  • Understand the key intellectual property issues affecting pharmaceutical industry agreements
  • Find out about the implications of SPCs for pharmaceutical industry agreements
  • Explore the current issues relating to IP including the Unified Patent Court and the challenges of Brexit
  • Learn how to draft contracts to avoid anti-trust infringement
  • Familiarise yourself with the key commercial and legal issues that affect pharmaceutical industry agreements
  • Gain knowledge of the key issues in clinical trial agreements, contract manufacturing agreements and co-promotion, co-marketing and distribution agreements
  • Update your practical skills when drafting effective collaboration agreements
  • Get to grips with the competitive nature of doing deals in the pharmaceutical industry and the tactics for effective and successful negotiation

Enrol now

The Drafting Commercial Contracts for the Pharmaceutical Industry course will cover:

Practical workshop: Intellectual property terms in collaboration and licensing agreements

  • Ownership of internally and externally generated IP
  • Joint ownership issues
  • Outsourcing issues
  • Improvements and grant backs
  • Sample clauses

The Unitary Patent, the Unified Patent Court and Brexit

  • What are the Unitary Patent and the Unified Patent Court?
  • What are the implications for pharmaceutical industry agreements?
  • The impact of Brexit

Supplementary protection certificates (SPCs) – securing the full commercial potential of your product

  • What are SPCs?
  • What are the implications for pharmaceutical industry agreements?
  • The duration of the SPC
  • What does the SPC cover?
  • Combination products
  • Basic patents and basic follow-on SPCs
  • Leveraging the full commercial value of your property

When does R&D infringe patents? Understanding experimental use and Bolar provisions

  • Limitations of experimental use defence to patent infringement
  • The ‘Euro Bolar’ defence: Article 10(6) Directive 2001/83/EC explained
  • The varying scope of the ‘Euro Bolar’ defence across the EU and how it has been implemented in UK law

Third-party IP rights – freedom-to-operate searches and implications for pharmaceutical industry agreements

  • Evaluating your freedom to operate
  • Different approaches to infringement in Europe
  • Assessment of injunction risk
  • Mitigating risk and pre-launch patent strategies more generally
  • Strategies for obtaining freedom to operate including via licensing
  • Freedom-to-operate warranties and indemnities
  • Payments and royalty stacking
  • Enforcement against infringers
  • No-challenge clauses
  • Benefits of recording your licence

Key issues in contract manufacturing agreements

  • The importance of the GMP audit
  • Issues with technology transfer
  • Apportionment of risk and reward
  • Secondary sources of supply
  • Building a supply chain
  • Other key issues

Key issues in co-promotion, co-marketing and distribution agreements

  • Introduction to the agreements
  • Scoping the deal
  • Preparing for contingencies and termination
  • Key characteristics of the distribution relationship
  • Key terms – scope of rights and responsibilities, restrictions, minimum purchase requirements, territory

Medicines regulations using regulatory processes to define contractual obligations

  • An introduction to regulatory law
  • Brief contrast of differing regulatory regimes: medicines/ devices
  • Milestones in approving medicines
  • Using regulatory processes and milestones in defining contractual obligations
  • Common pitfalls and hot spots

Key issues in clinical trials and related agreements

  • Outline of principal EU legislation
  • Structuring clinical trial agreements
  • Engaging CROs
  • Key agreement terms and obligations
  • Liability and indemnities

Workshop: Negotiating and drafting collaboration and licence agreements

Using a case scenario, participants will discuss issues relating to the negotiation and execution of a R&D collaboration, including:

  • Precontractual documents and the role of the term sheet
  • Scope of the licence
  • The interplay of key commercial terms, including:
    • governance and dispute resolution
    • performance obligations and termination rights
    • financial terms
  • Boilerplate clauses, including law and jurisdiction

Introduction to relevant EU competition law rules

  • Article 101 TFEU and 102 TFEU: restrictive agreements and practices and abuse of dominance in pharmaceutical markets
  • The December 2010 Horizontal Cooperation Guidelines
  • The Jan 2011 R&D Block Exemption – strategy for early joint research
  • The Technology Transfer Block Exemption – dos and don’ts for licensing in and out
  • The Vertical Agreements Block Exemption and Vertical Restraints Guidelines – designing distribution models in the EU
  • Specialisation Agreements Block Exemption
  • Implications of Brexit

Practical workshop: Current competition law issues

  • Reduced and exclusive distribution agreements
  • Licensing in and out
    • The new technology transfer exemption
  • Quota schemes and other devices for protecting domestic needs
  • Discount schemes for dominant companies

The rise and rise of the negotiator

Nothing exemplifies the modern pharma company as much as the growth of joint ventures, sub-contracting and licensing. All of these require the pharma executive to be able to negotiate and, often, to be able to lead others through the negotiation process.

  • The increase in negotiated relationships
  • Technical AND commercial skills
  • Recognising a negotiation
  • Great role models

Practical exercise: Negotiate and succeed & Structure for control

Working in teams, delegates are asked to resolve a multi-variable, multi-party business problem. The output of the exercise will form the backdrop for the following sessions on structure and influencing.

Structure for control

The research tells us that negotiation success is not related to any single aspect of the complex interactions that take place in any negotiation. However, above all else, the party that negotiates best gets the best result. The keys to negotiating well are controlling the negotiation and managing the process.

  • Control for success: key planning checklist to negotiate well
  • Structure for success: creating the space to agree
  • Trading for success: understanding relative values

Personal style and negotiation

This session helps us hold a mirror up so that participants can reflect on their own style. We look at why other styles irritate us – and how we negotiate with those people we find difficult to deal with.

  • Our lead style (and our fallback style)
  • The A to E of negotiating styles
  • Personal strengths and weaknesses

Practical exercise: Moving into engagement & Influencing and persuasion

Working in teams, delegates are asked to use their knowledge of their own style and those of others in their teams to agree strategies and tips for dealing with other styles and getting the most out of the negotiation.

Influencing and persuasion

It can be argued that the more we can influence someone to our position and the greater agreement we can build, the less we have to give away in our negotiation. This session looks at how people are persuaded and how the expert negotiator can use this knowledge to their benefit.

  • Persuasion psychology
  • The range of levers available
  • Focusing your persuasion

Enrol now

Niels Ersbøll

Niels Ersbøll, Partner, Arnold & Porter LLP, advises clients on EU competition law in relation to cartels and restrictive practices, merger control, abuse of dominance and State aid. He is currently involved in several pending EU cartel investigations. He advises on merger control investigations by the European Commission and competition authorities worldwide for clients such as General Electric, Boston Scientific, Pfizer, and Sanyo. Where investigations (mergers or cartels) are run by several authorities in parallel, he assists with overall strategy and coordination. Niels also has significant experience helping clients with designing and implementing compliance measures and conducting internal investigations and audits.

More details

Sean Constable

Sean Constable is an associate in the life sciences group at Mewburn Ellis LLP and is a European and Chartered Patent Attorney based in London. His work focusses on patent prosecution before the European Patent Office (EPO) and he has experience of both offensive and defensive opposition proceedings. He has experience filing and prosecuting patent applications on a broad variety of different technologies, with particular expertise in gene editing, protein engineering and antibody-based therapeutics. Sean also has experience working in-house at a biotechnology company in Cambridge, having been seconded there during his training and where he assisted the company with their patent portfolio and due diligence. He has a bachelor’s degree in Biochemistry from Imperial College London and a PhD in Neuroscience from University College London.

More details

Rob Maguire

Rob Maguire runs his own consultancy and his experience spans the full range of issues from developing an appropriate contract strategy and building a performance dashboard, to negotiation and conflict resolution to dealing with the inevitable management issues that arise in any long-term relationship. Through his consulting, coaching, mentoring and skills development interactions, he helps major organisations transform their approach to their commercial relationships.

More details

Mario Subramaniam

Mario Subramaniam is a senior associate in the life sciences and health transactional team at Pinsent Masons. As a former research scientist, he has a passion for the life sciences and has expertise in advising clients on intellectual property, commercial and regulatory aspects of the pharma, biotech, medtech and digital health sectors. He has advised on agreements that span the product life cycle, from strategic licensing transactions to research collaboration, clinical trial, manufacturing to supply and distribution. Having previously been in-house counsel at a number of prominent life science companies, Mario has a deep understanding of clients’ needs and is renowned for his clear and practical advice.

More details

Winsome Cheung

Winsome Cheung is an associate at Covington & Burling LLP assisting clients in the life sciences sector on their strategic transactions and investments, and intellectual property and commercial matters relating to the discovery, development, and commercialisation of their products. Winsome has a particular focus on the structuring, drafting, and negotiation of collaboration, co-development, license, and other complex strategic agreements, as well as manufacturing, clinical trial, and other agreements fundamental to the day-to-day running of life sciences businesses. She also advises on intellectual property and commercial aspects of M&A transactions and venture capital investments.

More details

Daniel Pavin

Daniel Pavin is a partner in the Corporate Practice of Covington & Burling LLP’s London office. He has broad non-contentious and contentious experience, with an emphasis on advising companies for whom intellectual property rights are of paramount importance. In particular, Daniel advises life sciences clients on their licensing, partnering, collaboration and other strategic and commercial agreements, and on the IP aspects of mergers, acquisitions and strategic investments in the life sciences and technology sectors.

More details

Stephen Reese

Stephen Reese is a partner at Clifford Chance and advises clients on both contentious and non-contentious intellectual property matters including patents, trade marks, trade secrets and copyright. Stephen represents and advises a broad range of clients in relation to the protection, exploitation and enforcement of their intellectual property rights. With significant experience representing clients within the life sciences and technology fields, Stephen has acted on some of the most significant licensing transactions in the life sciences industry. Since 2010, Stephen has been listed as one of IAM’s Top 250 Patent Licensing specialists.

More details

Colin McCall

Colin McCall is a partner in the IP/IT group at Taylor Wessing. His practice focuses on the life sciences and medtech sectors. Colin advises biotech, pharmaceutical and medtech companies ranging from early stage fast growth biotechs to listed multinational pharmaceutical and medical devices companies across the full range of commercial contracts – from general commercial agreements to the more complex manufacturing, R&D collaboration and licensing/partnering agreements. Colin also has particular expertise in advising on the commercial and intellectual property aspects of technology transactions including spin-outs, start-ups, venture capital investments, M&A and IPOs.

More details

Sarah Cowlishaw

Sarah Cowlishaw is an associate in the London Life Sciences group at Covington & Burling LLP. Her practice focuses on life sciences regulatory and commercial law for pharmaceutical, medical device, food and consumer products. Her advice on general regulatory matters includes borderline determinations, food classifications, adverse event and other reporting obligations, manufacturing controls and labelling and promotion. On the commercial side, she advises on the full range of agreements that span the product life-cycle in the life sciences sector. Sarah’s expertise includes clinical trial agreements, manufacturing and supply agreements, distribution and other marketing agreements and regulatory services agreements. She also regularly advises on regulatory aspects of corporate/commercial transactions, particularly regulatory due diligence.

More details

Ben Thomas

Ben Thomas is a Supervising Associate at Simmons & Simmons. He has experience of working across a range of contentious and non-contentious intellectual property matters, with a focus on patent and supplementary protection certificate litigation. Assisted by his strong technical background in biochemistry, Ben has a particular interest in the life sciences sector. He has acted for clients in a wide variety of industries, including pharmaceuticals, vaccines and medical devices, TMT and consumer goods (e.g. laundry detergents, vaping devices). He has acted for clients in disputes before the English Patents Court, the UK and European Union Intellectual Property Offices, and the General Court and Court of Justice of the European Union.

More details

James Agnew

James Agnew is a supervising associate at Simmons & Simmons. He has worked on a range of contentious and non-contentious intellectual property matters including commercial licensing, collaboration agreements, software protection, settlement proceedings and the intellectual property aspects of corporate transactions, financings and commercial arrangements. James also advises on life sciences regulatory issues including the promotion of medicines and devices and interactions with healthcare professionals. He has experience in a wide range of industries, including life sciences, TMT, finance, Fintech, energy and defence, with a focus on transactions involving intellectual property.

More details

Tom Carver

Tom Carver is a partner at White & Black Legal. He has broad experience in patent litigation (infringement and validity) in pharmaceuticals, medical and mechanical devices and electronics, including advice concerning threats provisions. Tom co-ordinates and manages litigation in multiple jurisdictions, and has particular expertise in biotech patent litigation. Tom has a degree in genetics and worked on the first patent case in the UK relating to genetically modified organisms, Monsanto v Cargill, and the first patent case in the UK on DNA sequences, Eli Lilly v Human Genome Sciences. He has been involved in some of the most significant patent cases in the UK in recent years. Tom lived in China for three years, where he managed intellectual property enforcement for Western clients, including Dyson. His experience includes patent (design, utility and invention), trade secret, trade mark and copyright litigation against companies in provinces across China in sectors including capital and consumer goods, cosmetics and medical devices. He also has experience of non-judicial IPR enforcement in China at trade fairs, online and by Customs seizures.

More details

Book Drafting Commercial Contracts for the Pharmaceutical Industry Live online/Classroom training

24-26 Nov 2021

Live online

09:30-17:30 UK (London) (UTC+00)
10:30-18:30 Paris (UTC+01)
04:30-12:30 New York (UTC-05)
Course code 11034

  • GBP 1,799
  • EUR 2,519
  • USD 2,806

View basket 

8-10 Feb 2022

Classroom
London venue TBC

09:00-17:30 UK (London)
Course code 11856

  • GBP 1,499 1,799
  • EUR 2,099 2,519
  • USD 2,338 2,806

Until 04 Jan

  • 3 days classroom-based training
  • Meet presenters and fellow attendees in person
  • Lunch and refreshments provided
  • Download documentation and certification of completion
  • Fair transfer and cancellation policy

View basket 

9-11 May 2022

Live online

09:30-17:30 UK (London) (UTC+01)
10:30-18:30 Paris (UTC+02)
04:30-12:30 New York (UTC-04)
Course code 11680

  • GBP 1,499 1,799
  • EUR 2,099 2,519
  • USD 2,338 2,806

Until 04 Apr

View basket 

8-10 Aug 2022

Classroom
London venue TBC

09:00-17:30 UK (London)
Course code 11857

  • GBP 1,499 1,799
  • EUR 2,099 2,519
  • USD 2,338 2,806

Until 04 Jul

  • 3 days classroom-based training
  • Meet presenters and fellow attendees in person
  • Lunch and refreshments provided
  • Download documentation and certification of completion
  • Fair transfer and cancellation policy

View basket 

23-25 Nov 2022

Live online

09:30-17:30 UK (London) (UTC+00)
10:30-18:30 Paris (UTC+01)
04:30-12:30 New York (UTC-05)
Course code 11858

  • GBP 1,499 1,799
  • EUR 2,099 2,519
  • USD 2,338 2,806

Until 19 Oct

View basket 

Reviews of IPI's Drafting Commercial Contracts for the Pharmaceutical Industry training course


This course was brilliant and covered all the key points. The speakers were highly knowledgeable and had practical insights and fresh perspectives on drafting issues and implications. Having multiple speakers allowed for a fresh and dynamic course, and increased the amount of information absorbed.

Nov 19 2019

James Langston
Contracts Manager, AstraZeneca

Nov 19 2019

Good overview of content, great organisation.

Amish Unka
Legal Counsel, Morningside Healthcare Limited

Jun 5 2019

High quality content and course materials. Professional presentation within a relaxed learning environment. Fantastic speakers who were happy to answer questions during their talks and the breaks.

Grace Hamlett
Legal Counsel, Mereo BioPharma

Nov 20 2018

Insightful teachers, great take-home material, stupendous learning environment.

Luis Briseno Roa
Associate Director, Alexion R&D France

Nov 20 2018

A fantastic program and great speakers/participants.

Mia Rensch-Jacobsen
Business Operations Manager, Roche Innovation Center Copenhagen

Jun 6 2018

All speakers are excellent and experts in their fields – I really enjoyed listening to them. The course is very extensive covering a wide variety of topics.

Avadhanula Yagna Praveen Kumar
Head of Intellectual Property Management, Pharmaniaga Berhad

Nov 20 2018

Very useful course for my future career.

Christopher France
Business Development Associate, GSK Vaccines Srl

Nov 20 2018

Great and useful course.

Taisier Adil
Legal Counsel, Xendo Holding B.V. – A ProPharma Group Company

Jun 6 2018

Good topics and speakers.

Wan Intan Idura Wan Ismail
Deputy Director, PHARMANIAGA BERHAD

Jun 6 2018

Excellent and immediately useful.

Dan Hudson
Manager, GSK Vaccines SRL

Jun 6 2018

I particularly liked the quality of the speakers and the various workshops.

Zian Bertrand
In-House Counsel , ERYTECH PHARMA

Nov 20 2017

I think that overall the course material was comprehensive and touched on a lot of different topics. I would recommend this course.

Angele Azzopardi
In House Legal Counsel , Starpharma Malta

Nov 20 2017

Very good course and good presentations/topics.

Ilaria Pastorello
Manager Vaccines Business Development, GSK Biologicals SA

Nov 20 2017

The content was very good and I appreciated the booklet provided. I found ... the speakers very engaging and everything was well organised and well presented.

Leah Baker
Pharmacovigilance Scientist, Norgine Ltd

Nov 20 2017

I found the course very practical and engaging

Tania Damianova
Company Lawyer, UCB S.A.

Jun 7 2017

The content is excellent. The speakers are highly qualified and talented in terms of lecturing.

Moataz Mahmoud
Legal & Compliance Advisor, EBN Sina Medical Establishment

Nov 20 2017

Very informative, very knowledgeable speakers, content good.

Luciana Schwambach
Contract Manufacturing Business Development Director, Xellia Pharmaceuticals ApS

Nov 20 2017

Very knowledgeable experts.

Olivia Chalwin
Major Contracts Manager, University of Southampton

Jun 7 2017

Very good, good alignment with professional practice.

Erik Popping
Corporate & Legal Counsel, Intravacc

Nov 23 2016

Great material and speakers

Paraskevi Sakallaridi
Lawyer, ELPEN Pharmaceutical Co. Inc.

Nov 23 2016

Good overall impression. Certain topics remained at introductory level without going into depth

Lina Yaneva
Legal Counsel, Mylan SAS

Jun 8 2016

The course was well organised. Unfortunately patent issues were skimmed over

Jeremy Whitman
Legal Department, Sterling S.p.A.

Nov 23 2016

Very interesting topics

Khady Seck
Mylan S.A.S.

Nov 18 2015

Very well organised, really enjoyed the higher energy speakers as I find it difficult to sit through three days if the speakers are low energy

Darragh O'Dea
Legal Counsel, BioMarin Pharmaceutical

Nov 18 2015

The course was good. I would suggest more practical examples.

Elda Selfo
Site Contract Specialist , INC Research

Nov 18 2015

Overall good. The seminar room with no windows and fresh air was the only negative.

Kristina Anna Reitmeier
European PharmInvent Services, s.r.o.

Jun 2 2015

Very professional. Some of the speaker were too fast, but all of them very friendly and kind.

Roberto Aldovini
Legal Counsel, APR Applied Pharma Research s.a

Jun 2 2015

Enough but not very deep

Eva Rosal Negre
Legal Advisor , Laboratories Hipra, S.A

Jun 2 2015

Organisations are paying a considerable amount for their employees to attend this course and the speakers should therefore deliver better presentations. The good speakers were engaging, interested in feedback and seemed to care. Given the professional level of the speakers the lack of professionalism in the way that they presented their subject in the time available was surprising.

Rachel Simpson
Contracts Manager, University of Dundee

Nov 18 2015

Days 1-2 were very detailed, although some presenters did not encourage interaction

Neil Thompson
Supply Chain Manager, Suir Pharma Ireland

Nov 19 2014

Generally high quality speakers. Good all-round refresher and networking opportunity.

Nick Plummer
Senior Director, EU Legal Services , Patheon UK Ltd

Nov 19 2014

The content was really interesting and useful, was communicated effectively and all the presenters were good. The negotiation part was great!

Eleni Pentafragka
ELPEN S.A.

Nov 19 2014

Very helpful for practising in-house lawyers courses. The negotiation strategies workshop should have been adapted to lawyers.

Maria Ganeva
Contracts Manager, Genzyme

Nov 19 2014

Speakers were fine and knew the subject well but some presentations were superficial

Maria Teresa Vazquez Calo
Lawyer, Assesora estudio jurídico y tributario S.L.P

Nov 19 2014

More case studies would be better

Jan Smidrkal
Tech Transfer Manager, Institute of Chemical Technology Prague

Jun 3 2014

Very good course, but many details covered in a short time.

Christopher Lambert
Chief Legal Officer, Fertin Pharma A/S

Nov 18 2013

The course was excellent, very useful and well organized.

Borislav Dakic
Director of Legal Department, Hemofarm AD

Nov 18 2013

Really excellent including Susan Sungleton

Patricia Hoyle
Global Head Intellectual Property, Evolva Holding SA

Jun 5 2013

Speakers were well prepared and had good presentation skills. I enjoyed the course.

Dragan Lutz
SENIOR LICENSING MANAGER, JADRAN-GALENSKI LABORATORIJ d.d.

Nov 18 2013

Content was useful, but I would recommend a bit more focus on generics as well. All speakers were competent and presented well.

Milica Milekic
Senior Legal Counsel, HEMOFARM AD

Jun 5 2013

Lots of content, some very good presentations and speakers.

Rebecca Flory
Solicitor, Edinburgh Research & Innovation Ltd

Nov 12 2012

Very relevant and useful to the topic of drafting commercial agreements in the pharma industry

Asif Altaf
Allergan Ltd

Nov 12 2012

Very helpful and detailed material, good coverage of all pharma legal issues considering time available.

Roberta Comerro
Ginsana SA

Nov 12 2012

Given the various topics being covered in a span of 3 days I think the speaker couldn't have done better

Sangeeta Shah
Mercury Pharma

UK

  • Torbay Pharmaceuticals
  • 3M Health Care Ltd
  • Adaptimmune Ltd
  • Allergan Ltd
  • Almac Group
  • Almac Group Limited
  • Apotex
  • Ark Therapeutics Ltd
  • Arnold & Porter (UK) LLP
  • Artios Pharma Limited
  • Astellas Pharma Europe Ltd
  • AstraZeneca
  • AstraZeneca (Macclesfield)
  • Bard Pharmaceuticals
  • Biofocus DPI
  • Boehringer
  • Boehringer Ingelheim Limited
  • Bristows LLP
  • Britannia Pharmaceuticals Ltd
  • British American Tobacco
  • Cancer Research UK
  • Centroflora CMS
  • Chemidex Pharma Limited
  • Clearly Gottlieb Steen & Hamilton
  • Clinuvel UK Ltd
  • CMC Biopharmaceuticals
  • CONSORT MEDICAL PLC
  • Covington & Burling
  • Covington & Burling LLP
  • Dechra Pharmaceuticals plc
  • Dexcel Pharma Ltd
  • Dickinson Dees LLP
  • Dishman Europe Ltd
  • Dr Reddys
  • Edinburgh Research & Innovation
  • Edinburgh Research & Innovation Ltd
  • Emergent Product Development UK Ltd
  • EUSA Pharma (UK) Ltd
  • Evox Therapeutics
  • Exactmer Ltd
  • F2G Ltd
  • Ferring Pharmaceuticals Ltd
  • GE Healthcare Limited
  • Genzyme Therapeutics Ltd
  • Gilead Sciences
  • GlaxoSmithKline
  • GlaxoSmithKline Services Unlimited
  • Glenmark Pharmaceuticals Europe R&F Ltd
  • GW Pharmaceuticals
  • IDIS Ltd
  • INC Research
  • Juniper Pharma Services Ltd
  • Kent Pharmaceuticals Ltd
  • Lonza Biologics
  • Merck Sharp and Dohme Limited
  • Mercury Pharma
  • Mereo BioPharma
  • Mitsubishi Tanabe Pharma Europe Ltd
  • Morningside Healthcare Limited
  • Muckle LLP
  • Mundipharma International Limited
  • Mylan
  • Mylan Inc
  • Napp
  • Napp Pharmaceutical Holdings Ltd
  • Napp Pharmaceuticals Ltd
  • Nicoventures Limited
  • Norbrook Laboratories
  • Norgine Ltd
  • Nottingham University Hospitals NHS Trust
  • Nova Laboratories Ltd
  • Novo Nordisk
  • Otsuka Pharmaceutical Europe Ltd
  • Oxagen Ltd
  • Oxford Biomedica
  • Patheon UK Ltd
  • Penn Pharma
  • Porton BioPharma
  • Porton Biopharma Ltd
  • QA Ltd
  • Randox Laboratories Limited
  • Roche Products Ltd
  • Servier Labs Ltd
  • Seven Seas Ltd
  • Sigma Aldrich Co Ltd
  • Synth-Isis Ltd
  • Takeda
  • Teva UK Ltd
  • The University of Edinburgh
  • Tillotts Pharma AG
  • UBC late stage(UK)Ltd
  • UCB Pharma
  • University of Dundee
  • University of Southampton
  • Vectura Ltd
  • Vertex Pharmaceuticals (Europe) Ltd
  • Vitabiotics Ltd
  • VWV
  • Warner Chilcott (UK) Ltd
  • West Pharmaceuticals Services Ltd

Switzerland

  • Acino International
  • Actelion Pharmaceutical Ltd
  • APR Applied Pharma Research s.a
  • Bachem AG
  • Biogen Idec
  • BUHLMANN LABORATORIES AG
  • CHEMO SA, Lugano Branch
  • CimArk SA
  • Clinuvel AG
  • Debiopharm International SA
  • DNDi
  • Drugs for Neglected Diseases initiative (DNDi)
  • Evolva Holding SA
  • F Hoffmann La Roche AG
  • F. Hoffmann-La Roche Ltd
  • Ferring International Center S.A.
  • Ginsana SA
  • Helsinn Chemicals SA
  • Helsinn Healthcare S.A.
  • Helsinn Healthcare SA
  • Merck Serono SA
  • MMV Medicines for Malaria Venture
  • Novartis Consumer health
  • Novartis Consumer Health S.A.
  • Novartis Pharma AG
  • Octapharma AG
  • OM Pharma SA
  • Siegfried AG
  • Siegfried Ltd
  • Stragen Pharma SA
  • Takeda Pharmaceuticals International GmbH
  • The Medicines Patent Pool Foundation
  • TILLOTTS AG
  • tillotts pharma AG
  • Vifor (International) Ltd.
  • Vifor Pharma Ltd.

Germany

  • 3M Deutschland GmbH
  • BERLIN-CHEMIE AG
  • Biontech AG
  • BioNTech Business Services GmbH
  • BioNTech SE
  • Biotest AG
  • Boehringer Ingelheim
  • Boehringer Ingelheim GmbH
  • Boehringer Ingelheim Pharma GmbH & Co. KG
  • Dr Kade Pharmazeutische Fabrik GmbH
  • Fresenius Medical Care
  • Fresenius SE & Co. KGaA
  • GPC Biotech AG
  • Graf von Westphalen
  • Grünenthal GmbH
  • Grünenthal Pharma GmbH & Co KG
  • Grünenthal Pharma GmbH & Co.KG
  • Intendis GmbH
  • Jerini AG
  • Morphosys AG
  • Mundipharma GmbH
  • Teva
  • Umicore AG & Co. KG
  • Vetter Pharma-Fertigung GmbH & Co KG
  • Wilex AG

Denmark

  • ALK-Abelló AS
  • Ascendis Pharma A/S
  • Chr. Hansen Holding A/S
  • Dako Denmark AS
  • Ferring Pharmaceuticals A/S
  • Fertin Pharma
  • Fertin Pharma A/S
  • Fertin Pharma AS
  • Genmab A/S
  • Genmab AS
  • Holst, Law Firm
  • Leo Pharma A S
  • LEO Pharma A/S
  • Leo Pharma AS
  • Novo Nordisk A/S
  • NsGene AS
  • Roche Innovation Center Copenhagen
  • Statens Serum Institut
  • Tech Trans Unit
  • Thrombologic ApS
  • Veloxis Pharmaceuticals AS
  • Xellia Pharmaceuticals
  • Xellia Pharmaceuticals ApS

France

  • Alexion R&D France
  • Aptargroup UK Holdings Limited
  • ERYtech Pharma
  • Flamel Technologies
  • Laboratoires Bouchara Recordati
  • LFB
  • LFB BIOMEDICAMENTS
  • MEDINCELL
  • Mylan
  • Mylan S.A.S.
  • Mylan SAS
  • none
  • Nordic Pharma SAS
  • RECIPHARM
  • Sanofi Aventis Group
  • Sanofi Aventis Groupe
  • Sanofi Aventis Recherche et Developpement
  • Sanofi-Aventis
  • Sanofi-Aventis Groupe
  • Takeda
  • TRANSGENE

Belgium

  • Ablynx
  • Ajino Moto - Omnichem
  • Ajinomoto Omnichem\_Omnichem Division
  • Celyad SA
  • GlaxoSmithKline
  • GlaxoSmithKline Biologicals SA
  • GSK
  • GSK Biologicals SA
  • Lonza Braine
  • UCB Biopharma SPRL
  • UCB Pharma
  • UCB Pharma SA
  • UCB S.A.
  • UCB SA
  • UCB SA/NV
  • VIB
  • VIB vzw

Netherlands

  • Astellas Pharma Europe B.V.
  • AMT BV
  • Crucell Holland BV
  • DSM Sinochem Pharmaceuticals Netherlands B.V
  • Friesland Consumer Products
  • Genzyme
  • Intravacc
  • Mimetas B.V.
  • PharmaMatch BV
  • Sandoz
  • Sanquin
  • Sun Pharmaceutical Industries Europe BV
  • Synthon BV
  • University Medical Center Utrecht
  • Xendo Holding B.V. – A ProPharma Group Company

Spain

  • Almirall, SA
  • Assesora estudio jurídico y tributario S.L.P
  • AstraZeneca Farmaceutica Spain, ss
  • Bioiberica SA
  • Chemo España
  • CHEMO ESPAÑA, S.L.
  • CHEMO Group
  • Corporación Medichem, SL
  • J Uriach y Compania SA
  • Laboratories Hipra, S.A
  • Laboratorios Almirall SA
  • Laboratorios Liconsa, SA
  • LACER SA
  • MEDICHEM S,A,

Italy

  • Angelini Farmaceutica
  • Aptuit (Verona) Srl
  • Covidien Italia SpA
  • Eli Lilly Italia Spa
  • Fondazione Centro San Raffaele Del Monte Tabor
  • GlaxoSmithKline
  • GSK Vaccines SRL
  • Molmed SpA
  • Recordati S.p.A
  • Roche SpA
  • Sterling S.p.A.
  • Studio Legale Lupi & Associati

Austria

  • AOP Orphan Pharma
  • Boehringer Ingelheim RCV GmbH & Co KG
  • Boehringer Ingelheim RCV GmbH&Co KG
  • Boehringer Ingelheim RCVGmbH & Co KG
  • Boehringer-Ingelheim RCV GmbH & Co KG
  • Ebewe Pharma
  • Eli Lilly Regional Operations
  • Intercell AG
  • Treibacher Industrie AG

Ireland

  • Abbott Ireland Ltd
  • BioMarin Pharmaceutical
  • Elan Pharma International Ltd
  • Horizon Therapeutics plc
  • Jazz Pharma
  • Jazz Pharmaceuticals
  • Pfizer Ireland Pharmaceuticals
  • Suir Pharma Ireland

Greece

  • ELPEN Pharmaceutical Co. Inc.
  • ELPEN S.A.
  • Genesis Pharma SA
  • Pharmathen SA
  • PharOS - Pharmaceutical Oriented Services
  • Scorinis Law Offices

Czech Republic

  • AstraZeneca Czech Republic sro
  • European PharmInvent Services, s.r.o.
  • Institute of Chemical Technology Prague
  • SOTIO a.s.

Portugal

  • ANGELINI FARMACEUTICA LDA
  • BIAL
  • BIAL - Portela & Companhia SA
  • Bluepharma Industria Farmaceutica SA

Russia

  • Abbott Products
  • GEROPHARM LLC
  • Ispen Pharma
  • Novartis Pharma LLC

Sweden

  • AstraZeneca
  • Astrazeneca Rod Ab
  • PCG Clinical Services
  • Recipharm AB (publ)

United States of America

  • Abbott Laboratories
  • Emergent BioSolutions
  • Grunenthal Latin America Inc.
  • Savara Inc.

Norway

  • Pharmaq AS
  • Pronova Biopharma AS
  • Pronova BioPharma Norge AS

Poland

  • Kancelaria Radcy Prawnego
  • Polpharma Trade Office
  • Zaklady Farmaceutyczne Polpharma SA

Ukraine

  • Acino Ukraine LLC, a company of Acino Group, Switzerland
  • Arterium Corporation
  • Farmak Joint Stock Company

Croatia

  • JADRAN-GALENSKI LABORATORIJ d.d.
  • Xellia d.o.o (Xellia Ltd)

Finland

  • Orion Corporation
  • Orion Corporation Orion Pharma

Korea, Republic Of

  • Celltrion Inc.
  • Samsung Bioepis

Romania

  • Roche Romania SRL
  • TEVA Pharmaceuticals

Serbia

  • Hemofarm AD
  • Quintiles doo Beograd

Turkey

  • K2 Events
  • MN Pharmaceuticals

Brazil

  • NOVO NORDISK FARMACÊUTICA DO BRASIL LTD

Bulgaria

  • Actavis EAD

Canada

  • Transition Therapeutics

Colombia

  • GrÜnenthal Colombiana

Cyprus

  • Medochemie Ltd

Hungary

  • Egis Pharmaceuticals PLC.

Jordan

  • Hikma Pharmaceuticals

Latvia

  • JSC Grindeks

Luxembourg

  • Menarini Int. Operations Luxembourg SA

Malaysia

  • PHARMANIAGA BERHAD

Malta

  • Starpharma Malta

Morocco

  • Novartis Pharma Maroc SA

Qatar

  • EBN Sina Medical Establishment

Slovenia

  • LEK Pharmaceuticals dd

United Arab Emirates

  • Gulf Pharmaceutical Industries (Julphar)

Enrol now

Multiple colleagues?
Talk to one of our training experts to discuss how to:

Run this course conveniently and cost-effectively in-house for your staff and colleagues

Aleksandra BEER
Training expert

+44 (0)20 7749 4749

inhouse@ipi.academy